Martin Cross

Novartis Australia Pty Ltd. engages in the marketing and wholesale of pharmaceutical products in Australia. The company is headquartered in North Ryde, Australia.

Alphapharm has been developing and making generic medicines in Australia for more than 25 years. Millions of Australians take an Alphapharm generic medicine every day. In fact, It has become the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme and Australia's leader in generic medicines. Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US. Globally, Alphapharm is part of Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third-largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.

Alphapharm has been developing and making generic medicines in Australia for more than 25 years. Millions of Australians take an Alphapharm generic medicine every day. In fact, It has become the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme and Australia's leader in generic medicines. Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US. Globally, Alphapharm is part of Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third-largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.